Carol Yepes/Moment via Getty Images
Cerevel Therapeutics (NASDAQ:CERE) reported that it, along with AbbVie
(NYSE:ABBV), has received Second Requests from the FTC for additional
information regarding their planned $8.7B merger.
This Second Request will extend the Hart-Scott-Rodino Act waiting period for the closing to 30 days after
the companies have substantially complied with the request, unless the companies choose to extend or
the period is terminated earlier by the FTC.
Despite the Second Request, Cerevel expressed confidence in the deal’s closure by mid-2024. The company
reinforced its anticipation by sharing that Cerevel shareholders had already approved the merger in
a special meeting held on February 16, according to an SEC filing.
In early December, AbbVie had revealed its intent to acquire Cerevel for $45 per share, equivalent to approximately
$8.7B in cash.
